In a phase 3 trial of 646 adults with OSA unable to use PAP, AD109 (aroxybutynin/atomoxetine) reduced AHI at 26 weeks vs placebo (difference -4.0 events/hour); PROMIS-Fatigue did not differ, and 21.2% vs 3.1% stopped for adverse events.
RCTn = 646
Strollo et al. Aroxybutynin and atomoxetine (AD109) for obstructive sleep apnea: a randomized phase 3 trial (SynAIRgy)